Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
The investment brings total capital raised to almost $300 million, the Menlo Park, California-based company said in a statement Wednesday. Investors in a previous financing round valued the biotech firm at more than $1 billion, according to Chief Executive Officer Ivan Dimov.
Orca’s lead drug candidate, called TRGFT-201, is a blend of stem and immune cells. The off-the-shelf therapy is made from healthy donor cells and is currently being tested in blood cancer patients, where the need is great, said ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.